DelveInsight’s “HER2+ Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the HER2+ Breast Cancer, historical and forecasted epidemiology as well as the HER2+ Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the HER2+ Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2+ Breast Cancer Market Forecast
Some of the key facts of the HER2+ Breast Cancer Market Report:
-
The HER2+ Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
In August 2023, Seagen Inc. (Nasdaq: SGEN) announced today that the Phase 3 HER2CLIMB-02 clinical study evaluating TUKYSA® (tucatinib) in conjunction with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) has successfully achieved its primary objective of progression-free survival (PFS). The trial involved patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer who had previously undergone treatment with a taxane and trastuzumab. While data regarding overall survival (OS), a secondary endpoint, are still pending maturity, there were more discontinuations due to adverse events in the combination arm of the trial. However, no new safety concerns emerged for the combination therapy.
-
As per data from the American Cancer Society and National Cancer Institute, HER2-positive (HER2+) breast cancers represent only around 14-15% of all cases of female breast cancer.
-
According to SEER statistics, the age-adjusted rate of new breast cancer cases for hormone receptor-positive (HR+)/HER2-positive (HER2+) breast cancer is 13.4 cases per 100,000 women, whereas for hormone receptor-negative (HR-)/HER2-positive breast cancer, it is 5.5 cases per 100,000 women.
-
Annually, approximately 2.5 million women in the UK undergo screening through the NHS Breast Screening Programme. Women aged 50 to 70, registered with a GP, receive invitations for a mammogram every three years.
-
Key HER2+ Breast Cancer Companies: UNICANCER, US Oncology Research, Latin American Cooperative Oncology Group, Herbert Lyerly, NSABP Foundation Inc, Shengjing Hospital, M.D. Anderson Cancer Center, Seagen Inc., Greenwich LifeSciences, Inc., CSPC ZhongQi Pharmaceutical, Sunnybrook Health Sciences Centre, Caigang Liu, Henan Cancer Hospital, Sichuan Baili Pharmaceutical, DualityBio Inc., German Breast Group, Ambrx, Inc., Eisai Inc., Bolt Biotherapeutics, Inc., Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., Sichuan Baili Pharmaceutical, and others
-
Key HER2+ Breast Cancer Therapies: DS-8201a, Trastuzumab, PHESGO, VRP-HER2, Doxorubicin, SHR-A1811, Zanidatamab, Tucatinib, GLSI-100, DP303c, Trastuzumab, ARX788, Utidelone Combined with Bevacizumab, BL-M07D1, DB-1303/BNT323, SYSA1901, Inavolisib, ARX788, BB-1701, BDC-1001, ZW25 (Zanidatamab), Trastuzumab Deruxtecan, RC48-ADC, BL-B01D1, and others
-
The HER2+ Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2+ Breast Cancer pipeline products will significantly revolutionize the HER2+ Breast Cancer market dynamics.
HER2+ Breast Cancer Overview
HER2-positive (HER2+) breast cancer is a subtype of breast cancer characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a receptor protein that plays a role in regulating cell growth and division. In HER2-positive breast cancer, the overexpression or amplification of HER2 leads to uncontrolled growth and proliferation of cancer cells.
Get a Free sample for the HER2+ Breast Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/her2-positive-breast-cancer-market
HER2+ Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
HER2+ Breast Cancer Epidemiology Segmentation:
The HER2+ Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of HER2+ Breast Cancer
-
Prevalent Cases of HER2+ Breast Cancer by severity
-
Gender-specific Prevalence of HER2+ Breast Cancer
-
Diagnosed Cases of Episodic and Chronic HER2+ Breast Cancer
Download the report to understand which factors are driving HER2+ Breast Cancer epidemiology trends @ HER2+ Breast Cancer Epidemiology Forecast
HER2+ Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2+ Breast Cancer market or expected to get launched during the study period. The analysis covers HER2+ Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the HER2+ Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
HER2+ Breast Cancer Therapies and Key Companies
-
DS-8201a: UNICANCER
-
Trastuzumab: US Oncology Research
-
PHESGO: Latin American Cooperative Oncology Group
-
VRP-HER2: Herbert Lyerly
-
Doxorubicin: NSABP Foundation Inc
-
SHR-A1811: Shengjing Hospital
-
Zanidatamab: M.D. Anderson Cancer Center
-
Tucatinib: Seagen Inc.
-
GLSI-100: Greenwich LifeSciences, Inc.
-
DP303c: CSPC ZhongQi Pharmaceutical
-
Trastuzumab: Sunnybrook Health Sciences Centre
-
ARX788: Caigang Liu
-
Utidelone Combined with Bevacizumab: Henan Cancer Hospital
-
BL-M07D1: Sichuan Baili Pharmaceutical
-
DB-1303/BNT323: DualityBio Inc.
-
SYSA1901: CSPC ZhongQi Pharmaceutical
-
Inavolisib: German Breast Group
-
ARX788: Ambrx, Inc.
-
BB-1701: Eisai Inc.
-
BDC-1001: Bolt Biotherapeutics, Inc.
-
ZW25 (Zanidatamab): Jazz Pharmaceuticals
-
Trastuzumab Deruxtecan: Daiichi Sankyo
-
RC48-ADC: RemeGen Co., Ltd.
-
BL-B01D1: Sichuan Baili Pharmaceutical
Discover more about therapies set to grab major HER2+ Breast Cancer market share @ HER2+ Breast Cancer Treatment Landscape
Scope of the HER2+ Breast Cancer Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key HER2+ Breast Cancer Companies: UNICANCER, US Oncology Research, Latin American Cooperative Oncology Group, Herbert Lyerly, NSABP Foundation Inc, Shengjing Hospital, M.D. Anderson Cancer Center, Seagen Inc., Greenwich LifeSciences, Inc., CSPC ZhongQi Pharmaceutical, Sunnybrook Health Sciences Centre, Caigang Liu, Henan Cancer Hospital, Sichuan Baili Pharmaceutical, DualityBio Inc., German Breast Group, Ambrx, Inc., Eisai Inc., Bolt Biotherapeutics, Inc., Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., Sichuan Baili Pharmaceutical, and others
-
Key HER2+ Breast Cancer Therapies: DS-8201a, Trastuzumab, PHESGO, VRP-HER2, Doxorubicin, SHR-A1811, Zanidatamab, Tucatinib, GLSI-100, DP303c, Trastuzumab, ARX788, Utidelone Combined with Bevacizumab, BL-M07D1, DB-1303/BNT323, SYSA1901, Inavolisib, ARX788, BB-1701, BDC-1001, ZW25 (Zanidatamab), Trastuzumab Deruxtecan, RC48-ADC, BL-B01D1, and others
-
HER2+ Breast Cancer Therapeutic Assessment: HER2+ Breast Cancer current marketed and HER2+ Breast Cancer emerging therapies
-
HER2+ Breast Cancer Market Dynamics: HER2+ Breast Cancer market drivers and HER2+ Breast Cancer market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
HER2+ Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, HER2+ Breast Cancer Market Access and Reimbursement
To know more about HER2+ Breast Cancer companies working in the treatment market, visit @ HER2+ Breast Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. HER2+ Breast Cancer Market Report Introduction
2. Executive Summary for HER2+ Breast Cancer
3. SWOT analysis of HER2+ Breast Cancer
4. HER2+ Breast Cancer Patient Share (%) Overview at a Glance
5. HER2+ Breast Cancer Market Overview at a Glance
6. HER2+ Breast Cancer Disease Background and Overview
7. HER2+ Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of HER2+ Breast Cancer
9. HER2+ Breast Cancer Current Treatment and Medical Practices
10. HER2+ Breast Cancer Unmet Needs
11. HER2+ Breast Cancer Emerging Therapies
12. HER2+ Breast Cancer Market Outlook
13. Country-Wise HER2+ Breast Cancer Market Analysis (2019–2032)
14. HER2+ Breast Cancer Market Access and Reimbursement of Therapies
15. HER2+ Breast Cancer Market Drivers
16. HER2+ Breast Cancer Market Barriers
17. HER2+ Breast Cancer Appendix
18. HER2+ Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/